Ro as patient journey control point

This move turns Ro from a drug seller into a control point for the patient journey. When branded GLP-1 supply shifted toward manufacturer run channels, Ro chose not to fight for its own supply lane. Instead it kept the intake, clinician review, messaging, dose management, and checkout inside its app, while Novo Nordisk and CenterWell handled the actual drug fulfillment. That lets Ro keep the patient touchpoints that matter most, without carrying inventory or building a manufacturer distribution program itself.

• The Wegovy integration made the model concrete. Ro announced in April 2025 that patients could get manufacturer sourced Wegovy inside the Ro app for $499 per month, with CenterWell dispensing on behalf of NovoCare. Ro owns the front end experience, but not the pharmacy rail underneath it.
  2 sacra 3 ro
• This was also a defensive response to commoditization. Ro, Hims & Hers, and LifeMD all gained access to manufacturer sourced Wegovy at the same cash price, which means drug access alone stopped being a moat. Competition shifted back to who can better manage onboarding, follow ups, labs, prior auth, and retention.
  1 sacra 2 sacra
• The economic logic is cleaner than the old compounded GLP-1 model. Ro can still charge for longitudinal obesity care while avoiding the regulatory and supply risk of sourcing product itself. That matters because GLP-1s had already become Ro's main growth engine, with about $370M in GLP-1 revenue in 2024 out of $598M total.
  1 sacra 4 sacra

Going forward, the winning telehealth companies in obesity will look less like standalone pharmacies and more like care orchestration layers plugged into manufacturer supply. If more drug makers copy Novo Nordisk and Lilly, Ro's advantage will come from being the place where patients start, stay, and manage treatment across months, even when fulfillment runs through someone else.